NSCLC Treatment Advance
Kelun-Biotech's Sac-TMT Plus Pembrolizumab Combination Shows Superiority in Phase III for NSCLC
Anonymous
Sichuan Kelun-Biotech has announced that its Phase III trial, OptiTROP-Lung06, hit its primary endpoint — a major win for patients with PD-L1-negative non-squamous non-small cell lung cancer (NSCLC), one of the hardest groups to treat with immunotherapy alone. The study showed that replacing standard chemotherapy with sacituzumab tirumotecan (sac-TMT) alongside the immunotherapy drug pembrolizumab was superior to the current first-line standard of care, according to Yahoo Finance.
The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. At the same time, Kelun-Biotech submitted a new drug indication to China's Center for Drug Evaluation (CDE), according to Barchart.
Why PD-L1-Negative Patients Are Hard to Treat
PD-L1 is a protein on tumor cells. Immunotherapy drugs like pembrolizumab work by blocking it. But when tumors have low or no PD-L1 expression, the immune system gets little signal to attack. That means standard immunotherapy largely fails this patient group.
Until now, doctors relied on combining pembrolizumab with pemetrexed and platinum-based chemotherapy. That regimen is effective but comes with significant toxicity. Kelun-Biotech's trial tested whether replacing that chemo backbone with sac-TMT — an antibody-drug conjugate, or ADC — could do better, according to ADVFN.
What Sac-TMT Does Differently as an ADC
Sac-TMT is an antibody-drug conjugate. Think of it as a guided missile. It targets a protein called Trop-2, which is found on many cancer cells. Once it locks on, it delivers a potent cell-killing payload directly to the tumor.
By pairing sac-TMT with pembrolizumab, Kelun-Biotech aims to unlock the immune response even in tumors that don't respond to immunotherapy alone. The idea is that the ADC kills cancer cells in a way that makes them more visible to the immune system, according to Yahoo Finance.
OptiTROP-Lung06 Trial Beats Standard of Care
The OptiTROP-Lung06 study compared two groups: patients receiving sac-TMT plus pembrolizumab versus those receiving the current standard — pembrolizumab with pemetrexed and platinum chemotherapy. The sac-TMT arm proved superior on the trial's primary endpoint, Barchart reported.
This result is significant because it suggests a chemo-free, ADC-based approach can outperform traditional regimens in this patient group. Kelun-Biotech said the strategy is expected to "unlock the therapeutic potential" of PD-1 blockers like pembrolizumab in patients with limited immune responses, according to ADVFN.
ASCO Presentation and CDE Filing Signal Next Steps
The trial data was presented at ASCO 2025, one of the world's most watched oncology conferences. Presenting there puts the findings in front of global oncologists and regulators at once.
Simultaneously, Kelun-Biotech filed for a new indication with China's CDE — the agency that approves drug uses in the country. If approved, sac-TMT plus pembrolizumab could become a new first-line standard for PD-L1-negative non-squamous NSCLC patients in China, according to Yahoo Finance Singapore.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
4
Articles
3
Reach
4
Topics
A
AnonymousAuthor